{"id":24338,"date":"2026-02-28T22:53:50","date_gmt":"2026-03-01T02:53:50","guid":{"rendered":"https:\/\/cliniqueomicron.ca\/anticoagulants-circulants-lupiques\/"},"modified":"2026-03-01T16:55:05","modified_gmt":"2026-03-01T20:55:05","slug":"lupus-anticoagulants","status":"publish","type":"page","link":"https:\/\/cliniqueomicron.ca\/en\/anticoagulants-circulants-lupiques\/","title":{"rendered":"Lupus Anticoagulants: Diagnosis and Significance | Omicron Clinic"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"24338\" class=\"elementor elementor-24338\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bb88700 e-flex e-con-boxed e-con e-parent\" data-id=\"bb88700\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;ekit_has_onepagescroll_dot&quot;:&quot;yes&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-da338a4 elementor-widget elementor-widget-html\" data-id=\"da338a4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;ekit_we_effect_on&quot;:&quot;none&quot;}\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap');\n\n.co-wrap * {\n  font-family: 'Poppins', sans-serif;\n  box-sizing: border-box;\n}\n.co-wrap {\n  max-width: 1100px;\n  margin: 0 auto;\n  padding: 30px 0 60px;\n  margin-top: 10px;\n}\n.co-label {\n  font-family: 'Cinzel', serif;\n  font-size: 14px;\n  font-weight: bold;\n  letter-spacing: 1px;\n  text-transform: uppercase;\n  color: #4D6577;\n  margin-bottom: 14px;\n  display: block;\n}\n.co-wrap h1 {\n  font-size: 32px;\n  font-weight: 500;\n  color: #323C52;\n  margin: 0 0 22px;\n  line-height: 1.2;\n  letter-spacing: 0.5px;\n}\n.co-intro {\n  font-size: 16px;\n  font-weight: 400;\n  line-height: 1.75;\n  color: #4D6577;\n  margin-bottom: 36px;\n  padding-bottom: 32px;\n  border-bottom: 1px solid rgba(77,101,119,.2);\n}\n.co-wrap h2 {\n  font-size: 20px;\n  font-weight: 600;\n  color: #323C52;\n  margin: 32px 0 12px;\n  letter-spacing: 0.3px;\n}\n.co-wrap p {\n  font-size: 15px;\n  font-weight: 400;\n  color: #4D6577;\n  line-height: 1.7;\n  margin-bottom: 14px;\n}\n.co-list {\n  list-style: none;\n  padding: 0;\n  margin: 12px 0 24px;\n}\n.co-list li {\n  font-size: 15px;\n  font-weight: 400;\n  color: #4D6577;\n  padding: 10px 14px 10px 38px;\n  margin-bottom: 8px;\n  border-radius: 6px;\n  position: relative;\n  background: rgba(77,101,119,.06);\n  border-left: 3px solid #4D6577;\n}\n.co-list li::before {\n  content: \"\u2713\";\n  position: absolute;\n  left: 12px;\n  font-weight: 700;\n  color: #4D6577;\n}\n.co-table {\n  width: 100%;\n  border-collapse: collapse;\n  margin: 14px 0 22px;\n  font-size: 14px;\n  border-radius: 8px;\n  overflow: hidden;\n}\n.co-table thead tr {\n  background: #323C52;\n  color: #fff;\n}\n.co-table thead th {\n  padding: 11px 16px;\n  text-align: left;\n  font-weight: 600;\n  font-size: 13px;\n}\n.co-table tbody tr:nth-child(even) { background: rgba(77,101,119,.06); }\n.co-table tbody tr:nth-child(odd) { background: #fff; }\n.co-table td {\n  padding: 10px 16px;\n  color: #4D6577;\n  border-bottom: 1px solid rgba(77,101,119,.12);\n  font-size: 14px;\n  vertical-align: top;\n}\n.co-table td:first-child {\n  font-weight: 600;\n  color: #323C52;\n}\n.co-infobox {\n  display: flex;\n  gap: 12px;\n  background: rgba(77,101,119,.06);\n  border-radius: 8px;\n  border-left: 4px solid #4D6577;\n  padding: 14px 18px;\n  margin: 18px 0 28px;\n  font-size: 14px;\n  font-weight: 400;\n  color: #4D6577;\n  line-height: 1.65;\n}\n.co-infobox .ico { font-size: 18px; flex-shrink: 0; }\n.co-urgence {\n  background: #fff8f8;\n  border-left: 5px solid #c0392b;\n  border-radius: 6px;\n  padding: 20px 26px;\n  margin: 24px 0 32px;\n}\n.co-urgence .co-urgence-titre {\n  font-size: 13px;\n  font-weight: 700;\n  color: #c0392b;\n  letter-spacing: 1.5px;\n  text-transform: uppercase;\n  margin-bottom: 10px;\n}\n.co-urgence p {\n  color: #5a2020;\n  font-size: 14px;\n  margin: 0 0 10px;\n  line-height: 1.7;\n}\n.co-urgence p:last-child { margin-bottom: 0; }\n.co-urgence .co-urgence-num {\n  font-size: 28px;\n  font-weight: 700;\n  color: #c0392b;\n  letter-spacing: 2px;\n  display: block;\n}\n<\/style>\n\n<div class=\"co-wrap\">\n\n  <span class=\"co-label\">H\u00e9matologie \u2013 Coagulation et maladies auto-immunes<\/span>\n  <h1>Circulating lupus anticoagulants<\/h1>\n\n  <div class=\"co-intro\">\n    Les anticoagulants circulants lupiques (ACL), aussi d\u00e9sign\u00e9s par le terme anglais <em>Lupus anticoagulant<\/em> (LA) are autoantibodies directed against phospholipid-protein complexes involved in the coagulation cascade. Their name is confusing: although they prolong measured coagulation times <em>in vitro<\/em>, they are associated, <em>in vivo<\/em>, to a marked procoagulant state, favoring venous and arterial thrombosis. They constitute one of the three biological criteria for antiphospholipid syndrome (APS), alongside anticardiolipin IgG\/IgM and anti-beta-2-glycoprotein I IgG\/IgM antibodies. First described in patients with systemic lupus erythematosus (SLE), they can also occur in isolation, without identifiable connective tissue disease, or transiently following an infection or medication. Their detection relies on a structured multi-step biological algorithm, due to the absence of a single test that is sufficiently sensitive and specific. As a diagnostic criterion for APS, their presence must be confirmed on two separate samples taken at least 12 weeks apart.\n  <\/div>\n\n  <div class=\"co-urgence\">\n    <div class=\"co-urgence-titre\">Medical emergencies<\/div>\n    <p>Toute suspicion de thrombose veineuse profonde, d'embolie pulmonaire ou d'accident vasculaire c\u00e9r\u00e9bral chez un patient porteur d'anticoagulants circulants lupiques repr\u00e9sente une urgence m\u00e9dicale n\u00e9cessitant une \u00e9valuation hospitali\u00e8re imm\u00e9diate.<\/p>\n  <\/span>\n  <\/div>\n\n  <h2>M\u00e9canisme d'action et paradoxe biologique<\/h2>\n  <p>Les anticoagulants circulants lupiques se lient aux phospholipides anioniques et aux prot\u00e9ines plasmatiques associ\u00e9es, notamment la b\u00eata-2-glycoprot\u00e9ine I et la prothrombine. Cette liaison interf\u00e8re avec l'assemblage des complexes enzymatiques de la coagulation sur les surfaces phospholipidiques, prolongeant ainsi les temps de coagulation mesur\u00e9s dans les tests biologiques r\u00e9alis\u00e9s en laboratoire.<\/p>\n  <p>Paradoxically, this inhibition <em>in vitro<\/em> does not translate to an anticoagulant effect <em>in vivo<\/em>. On the contrary, aCL disrupt natural anticoagulant mechanisms, activate platelets and endothelial cells, and promote a prothrombotic state. This paradox is the reason for the misleading name of these antibodies, and it is important to understand it to correctly interpret coagulation results in a patient with aCL.<\/p>\n\n  <div class=\"co-infobox\">\n    <span class=\"ico\">\u2139\ufe0f<\/span>\n    <span>Un patient porteur d'anticoagulants circulants lupiques peut pr\u00e9senter un temps de c\u00e9phaline activ\u00e9e (TCA) allong\u00e9 \u00e0 la biologie, sans saignement clinique. Cet allongement ne refl\u00e8te pas un risque h\u00e9morragique accru, mais bien un risque thrombotique \u00e9lev\u00e9. Cette distinction est cliniquement fondamentale.<\/span>\n  <\/div>\n\n  <h2>Indications au d\u00e9pistage<\/h2>\n  <p>La recherche des ACL est indiqu\u00e9e dans plusieurs contextes cliniques, en particulier lorsqu'une thrombophilie auto-immune ou un syndrome des antiphospholipides est suspect\u00e9.<\/p>\n\n  <ul class=\"co-list\">\n    <li>Thrombose veineuse profonde ou embolie pulmonaire, notamment chez un patient jeune ou sans facteur d\u00e9clenchant \u00e9vident<\/li>\n    <li>Accident vasculaire c\u00e9r\u00e9bral isch\u00e9mique ou accident isch\u00e9mique transitoire (AIT) chez un patient de moins de 55 ans<\/li>\n    <li>Thrombose art\u00e9rielle dans un territoire inhabituel (m\u00e9sent\u00e9rique, r\u00e9nale, surr\u00e9nalienne)<\/li>\n    <li>Fausses couches spontan\u00e9es r\u00e9currentes ou mort f\u0153tale in utero inexpliqu\u00e9e<\/li>\n    <li>Allongement inexpliqu\u00e9 du TCA non corrig\u00e9 par l'ajout de plasma normal (test de m\u00e9lange)<\/li>\n    <li>Lupus \u00e9ryth\u00e9mateux syst\u00e9mique ou autre connectivite connue, en bilan immunologique initial<\/li>\n    <li>Thrombop\u00e9nie auto-immune sans autre cause identifi\u00e9e<\/li>\n  <\/ul>\n\n  <h2>Algorithme de d\u00e9tection en laboratoire<\/h2>\n  <p>La d\u00e9tection des ACL ne repose pas sur un test unique. Les lignes directrices internationales de la Soci\u00e9t\u00e9 internationale de thrombose et d'h\u00e9mostase (ISTH) recommandent un algorithme en trois \u00e9tapes successives, r\u00e9alis\u00e9es sur un plasma pauvre en plaquettes obtenu par double centrifugation.<\/p>\n\n  <table class=\"co-table\">\n    <thead>\n      <tr>\n        <th>\u00c9tape<\/th>\n        <th>Test r\u00e9alis\u00e9<\/th>\n        <th>Principle<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td>1. Tests de d\u00e9pistage<\/td>\n        <td>TCA sensible, temps de venin de vip\u00e8re Russell dilu\u00e9 (dRVVT screen)<\/td>\n        <td>Mettre en \u00e9vidence un allongement des temps de coagulation phospholipide-d\u00e9pendants<\/td>\n      <\/tr>\n      <tr>\n        <td>2. Test de m\u00e9lange<\/td>\n        <td>M\u00e9lange plasma du patient et plasma normal (1:1)<\/td>\n        <td>V\u00e9rifier que l'allongement n'est pas corrig\u00e9, confirmant la pr\u00e9sence d'un inhibiteur circulant plut\u00f4t qu'un facteur d\u00e9ficitaire<\/td>\n      <\/tr>\n      <tr>\n        <td>3. Confirmation test<\/td>\n        <td>dRVVT confirm (exc\u00e8s de phospholipides), test d'hexagonalisation<\/td>\n        <td>D\u00e9montrer la d\u00e9pendance aux phospholipides de l'inhibition, sp\u00e9cifique des ACL<\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n\n  <p>Un r\u00e9sultat est consid\u00e9r\u00e9 positif pour les ACL uniquement si les trois \u00e9tapes sont concluantes selon les crit\u00e8res ISTH. Un seul test anormal ne suffit pas \u00e0 confirmer leur pr\u00e9sence.<\/p>\n\n  <div class=\"co-infobox\">\n    <span class=\"ico\">\u2139\ufe0f<\/span>\n    <span>La d\u00e9tection des ACL est significativement perturb\u00e9e par la pr\u00e9sence d'anticoagulants th\u00e9rapeutiques : h\u00e9parine, warfarine et anticoagulants oraux directs (rivaroxaban, apixaban, dabigatran). Dans la mesure du possible, le pr\u00e9l\u00e8vement doit \u00eatre r\u00e9alis\u00e9 \u00e0 distance d'un traitement anticoagulant ou des neutralisants sp\u00e9cifiques doivent \u00eatre utilis\u00e9s au laboratoire.<\/span>\n  <\/div>\n\n  <h2>Results Interpretation<\/h2>\n\n  <table class=\"co-table\">\n    <thead>\n      <tr>\n        <th>Results<\/th>\n        <th>Meaning<\/th>\n        <th>Usual conduct<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td>Positif confirm\u00e9 (\u00d7 2, \u00e0 12 semaines)<\/td>\n        <td>Crit\u00e8re biologique de SAPL \u00e9tabli<\/td>\n        <td>\u00c9valuation clinique compl\u00e8te, bilan antiphospholipide, suivi sp\u00e9cialis\u00e9<\/td>\n      <\/tr>\n      <tr>\n        <td>Positif \u00e0 un seul pr\u00e9l\u00e8vement<\/td>\n        <td>Positivit\u00e9 transitoire possible (infection, m\u00e9dicament)<\/td>\n        <td>Contr\u00f4le obligatoire \u00e0 12 semaines avant toute conclusion diagnostique<\/td>\n      <\/tr>\n      <tr>\n        <td>Negative<\/td>\n        <td>ACL absent au moment du pr\u00e9l\u00e8vement<\/td>\n        <td>N'exclut pas un SAPL si anticardiolipines ou anti-b\u00eata2GPI positifs<\/td>\n      <\/tr>\n      <tr>\n        <td>Non interpr\u00e9table<\/td>\n        <td>Interf\u00e9rence par anticoagulants th\u00e9rapeutiques ou pr\u00e9l\u00e8vement inad\u00e9quat<\/td>\n        <td>R\u00e9p\u00e9ter dans des conditions optimales ; mentionner les traitements en cours<\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n\n  <h2>Risk profiles in antiphospholipid syndrome<\/h2>\n  <p>La valeur pronostique des ACL varie selon leur association avec les autres anticorps antiphospholipides. Le risque thrombotique est stratifi\u00e9 selon le nombre de marqueurs positifs et leur persistance.<\/p>\n\n  <table class=\"co-table\">\n    <thead>\n      <tr>\n        <th>Profil s\u00e9rologique<\/th>\n        <th>Thrombotic risk level<\/th>\n      <\/tr>\n    <\/thead>\n    <tbody>\n      <tr>\n        <td>ACL seul, positif isol\u00e9<\/td>\n        <td>Risque mod\u00e9r\u00e9 ; \u00e0 contextualiser cliniquement<\/td>\n      <\/tr>\n      <tr>\n        <td>ACL + anticardiolipines (double positivit\u00e9)<\/td>\n        <td>Risque \u00e9lev\u00e9<\/td>\n      <\/tr>\n      <tr>\n        <td>ACL + anti-b\u00eata2GPI (double positivit\u00e9)<\/td>\n        <td>Risque \u00e9lev\u00e9<\/td>\n      <\/tr>\n      <tr>\n        <td>Triple positivit\u00e9 (ACL + anticardiolipines + anti-b\u00eata2GPI)<\/td>\n        <td>Risque tr\u00e8s \u00e9lev\u00e9 ; profil associ\u00e9 au taux de r\u00e9cidive thrombotique le plus important<\/td>\n      <\/tr>\n    <\/tbody>\n  <\/table>\n\n  <div class=\"co-infobox\">\n    <span class=\"ico\">\u2139\ufe0f<\/span>\n    <span>Parmi les trois crit\u00e8res biologiques du SAPL, les anticoagulants circulants lupiques sont consid\u00e9r\u00e9s comme le marqueur le plus fortement associ\u00e9 au risque thrombotique, devant les anticardiolipines et les anti-b\u00eata-2-glycoprot\u00e9ine I, selon les donn\u00e9es des grandes cohortes internationales.<\/span>\n  <\/div>\n\n  <h2>Causes de positivit\u00e9 transitoire ou non li\u00e9e au SAPL<\/h2>\n  <p>La pr\u00e9sence d'ACL n'est pas toujours synonyme de SAPL. Plusieurs situations peuvent entra\u00eener une positivit\u00e9 transitoire ou non pathologique, d'o\u00f9 l'importance de confirmer syst\u00e9matiquement le r\u00e9sultat \u00e0 12 semaines.<\/p>\n\n  <ul class=\"co-list\">\n    <li>Infections virales aigu\u00ebs : VIH, h\u00e9patite C, virus d'Epstein-Barr, cytom\u00e9galovirus<\/li>\n    <li>Infections bact\u00e9riennes : syphilis, borr\u00e9liose, tuberculose<\/li>\n    <li>M\u00e9dicaments : ph\u00e9nothiazines, hydralazine, proca\u00efnamide, certains antibiotiques<\/li>\n    <li>N\u00e9oplasies h\u00e9matologiques et tumeurs solides<\/li>\n    <li>Connectivites autres que le lupus : syndrome de Sj\u00f6gren, polyarthrite rhumato\u00efde<\/li>\n    <li>Sujet \u00e2g\u00e9 sans ant\u00e9c\u00e9dent thrombotique ni connectivite identifiable<\/li>\n  <\/ul>\n\n  <h2>Bilan compl\u00e9mentaire associ\u00e9<\/h2>\n  <p>La d\u00e9tection d'ACL positifs s'inscrit dans un bilan antiphospholipide complet, compl\u00e9t\u00e9 selon le contexte clinique par d'autres investigations immunologiques et thrombophiliques.<\/p>\n\n  <ul class=\"co-list\">\n    <li>Anticardiolipin IgG and IgM by ELISA<\/li>\n    <li>Anti-b\u00eata-2-glycoprot\u00e9ine I IgG et IgM<\/li>\n    <li>Anticorps antinucl\u00e9aires (ANA) avec profil d'immunofluorescence<\/li>\n    <li>Compl\u00e9ment C3, C4 et CH50 en contexte de lupus suspect\u00e9<\/li>\n    <li>FSC avec num\u00e9ration plaquettaire (thrombop\u00e9nie associ\u00e9e possible)<\/li>\n    <li>Bilan de thrombophilie g\u00e9n\u00e9tique selon le tableau clinique : facteur V Leiden, mutation G20210A de la prothrombine<\/li>\n    <li>Imagerie selon la localisation de la thrombose suspect\u00e9e<\/li>\n  <\/ul>\n\n  <h2>Consult at Clinique Omicron<\/h2>\n  <p>Clinique Omicron dispose de points de service au Qu\u00e9bec o\u00f9 les patients peuvent obtenir une \u00e9valuation m\u00e9dicale et un bilan biologique incluant la recherche d'anticoagulants circulants lupiques. Les m\u00e9decins et infirmi\u00e8res praticiennes sp\u00e9cialis\u00e9es (IPS) de la clinique assurent la prescription des tests appropri\u00e9s et l'orientation vers les sp\u00e9cialistes selon le tableau clinique. Pour prendre rendez-vous dans l'une des succursales au Qu\u00e9bec, visitez cliniqueomicron.ca ou communiquez directement avec la clinique.<\/p>\n\n  <style>.co-disclaimer{font-size:13px;color:#8a9aaa;font-style:italic;border-top:1px solid rgba(77,101,119,.15);padding-top:24px;margin-top:40px;line-height:1.6;}<\/style>\n  <p class=\"co-disclaimer\">The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.<\/p>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>H\u00e9matologie \u2013 Coagulation et maladies auto-immunes Anticoagulants circulants lupiques Les anticoagulants circulants lupiques (ACL), aussi d\u00e9sign\u00e9s par le terme anglais lupus anticoagulant (LA), sont des auto-anticorps dirig\u00e9s contre des complexes phospholipides-prot\u00e9ines impliqu\u00e9s dans la cascade de coagulation. Leur nom pr\u00eate \u00e0 confusion : bien qu&rsquo;ils allongent les temps de coagulation mesur\u00e9s in vitro, ils sont&hellip;&nbsp;<a href=\"https:\/\/cliniqueomicron.ca\/en\/anticoagulants-circulants-lupiques\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Lupus Anticoagulants: Diagnosis and Significance | Omicron Clinic<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":100,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"_metasync_otto_title":"Anticoagulants circulants lupiques : Diagnostic et services | Clinique Omicron","_metasync_otto_description":"Les anticoagulants circulants lupiques sont des marqueurs cl\u00e9s du syndrome des antiphospholipides. D\u00e9couvrez leur r\u00f4le, leur d\u00e9tection et leur port\u00e9e clinique.","_metasync_otto_keywords":"anticoagulants circulants lupiques, syndrome des antiphospholipides, diagnostic lupus anticoagulant, gestion des anticoagulants, clinique de lupus, implications cliniques des anticoagulants, services de diagnostic, Clinique Omicron","_metasync_otto_og_title":"Anticoagulants circulants lupiques | Brossard | Clinique Omicron","_metasync_otto_og_description":"","_metasync_otto_twitter_title":"Anticoagulants circulants lupiques | Brossard | Clinique Omicron","_metasync_otto_twitter_description":"Les anticoagulants circulants lupiques sont des marqueurs cl\u00e9s du syndrome des antiphospholipides. D\u00e9couvrez leur r\u00f4le, leur d\u00e9tection et leur port\u00e9e clinique.","rank_math_title":"","rank_math_description":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_aioseo_title":"Anticoagulants circulants lupiques : diagnostic et signification | Clinique Omicron","_aioseo_description":"Les anticoagulants circulants lupiques sont des marqueurs cl\u00e9s du syndrome des antiphospholipides. D\u00e9couvrez leur r\u00f4le, leur d\u00e9tection et leur port\u00e9e clinique.","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"{\"aioseo\":\"2026-05-10T07:38:58+00:00\"}","_metasync_robots_advanced":"","footnotes":""},"class_list":["post-24338","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/comments?post=24338"}],"version-history":[{"count":4,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24338\/revisions"}],"predecessor-version":[{"id":25586,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24338\/revisions\/25586"}],"wp:attachment":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/media?parent=24338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}